ESMO 2021

16–21 September 2021 | Virtual Meeting
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

🎥 @GeorgetteOni of NHS Nottingham Breast Institute talks on supporting future generations of healthcare professionals

Watch: 👉http://ow.ly/LwxB50LQ3p0👈

@UKONSmember #UKONS2022 #Nursing #OncologyNursing

Reply on Twitter 1598709591365255173Retweet on Twitter 1598709591365255173Like on Twitter 1598709591365255173Twitter 1598709591365255173
Retweet on TwitterVJ Oncology Retweeted
myESMOESMO - Eur. Oncology@myESMO·
December 2, 2022

"As an oncology community, we must rise to the task today of laying the foundations for sustainable, high-quality #CancerCare that will remain accessible tomorrow", @peters_solange said at the Opening Ceremony for #ESMOAsia22.
👉http://ow.ly/XAbU50LTahQ

Reply on Twitter 1598557206957506561Retweet on Twitter 15985572069575065615Like on Twitter 159855720695750656131Twitter 1598557206957506561
Retweet on TwitterVJ Oncology Retweeted
pashtoonkasiPashtoon Kasi MD, MS@pashtoonkasi·
December 2, 2022

🧐TOPAZ-1➡️685 patients.
👇🏾Biomarker analysis👇🏾441 patients.
🛑244 (35.6%)‼️ testing NOT completed?

IDH1 8.8%
HER2 7.9%
FGFR2 3.4%
BRAF 3.6%
BRCA 4.3%
More realistic of real🌍numbers in 1st line.

💡upfront #ctDNA✅ 💯 ➡️you’ll find more. @OncoAlert @curecc #ESMOAsia22 @myESMO https://twitter.com/jdekervel/status/1598599792749600770

Jeroen Dekervel@JDekervel

Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1. Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22 2

Reply on Twitter 1598644651665268736Retweet on Twitter 15986446516652687369Like on Twitter 159864465166526873634Twitter 1598644651665268736
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

#SABCS22 starts in only a couple of days!

Stay tuned right here 👉http://VJOncology.com👈 which will be updated soon on all the latest in #BreastCancer 👩‍⚕‍🎥🎙

@VJOncology @SABCSSanAntonio @AACR #BreastCancer #BCsm #OncoAlert

Reply on Twitter 1598694368269025282Retweet on Twitter 1598694368269025282Like on Twitter 15986943682690252822Twitter 1598694368269025282
Retweet on TwitterVJ Oncology Retweeted
matteolambeMatteo Lambertini, MD PhD@matteolambe·
December 2, 2022

Great comprehensive presentation by super @RebeccaDSing at #ESMOasia22 on #immunotherapy in early triple-negative #BreastCancer: important citation for the recent review by @ElisaAgostinett & the great algorithm for #TNBC treatment by @hoperugo

@OncoAlert @myESMO #bcsm #ImmOnc

4
Reply on Twitter 1598530488737619971Retweet on Twitter 15985304887376199716Like on Twitter 159853048873761997119Twitter 1598530488737619971
Load More

ESMO 2021

16–21 September 2021 | Virtual Meeting
The European Society for Medical Oncology (ESMO) 2021 annual meeting was held virtually this year between 16-21 September and showcased the very latest advances in the treatment of cancer. Catch up on key trial updates including results from the practice-changing PEACE-1, and DESTINY-Breast03 studies as well as our in-person roundtable discussions on the most important data.
View all videos
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

🎥 @GeorgetteOni of NHS Nottingham Breast Institute talks on supporting future generations of healthcare professionals

Watch: 👉http://ow.ly/LwxB50LQ3p0👈

@UKONSmember #UKONS2022 #Nursing #OncologyNursing

Reply on Twitter 1598709591365255173Retweet on Twitter 1598709591365255173Like on Twitter 1598709591365255173Twitter 1598709591365255173
Retweet on TwitterVJ Oncology Retweeted
myESMOESMO - Eur. Oncology@myESMO·
December 2, 2022

"As an oncology community, we must rise to the task today of laying the foundations for sustainable, high-quality #CancerCare that will remain accessible tomorrow", @peters_solange said at the Opening Ceremony for #ESMOAsia22.
👉http://ow.ly/XAbU50LTahQ

Reply on Twitter 1598557206957506561Retweet on Twitter 15985572069575065615Like on Twitter 159855720695750656131Twitter 1598557206957506561
Retweet on TwitterVJ Oncology Retweeted
pashtoonkasiPashtoon Kasi MD, MS@pashtoonkasi·
December 2, 2022

🧐TOPAZ-1➡️685 patients.
👇🏾Biomarker analysis👇🏾441 patients.
🛑244 (35.6%)‼️ testing NOT completed?

IDH1 8.8%
HER2 7.9%
FGFR2 3.4%
BRAF 3.6%
BRCA 4.3%
More realistic of real🌍numbers in 1st line.

💡upfront #ctDNA✅ 💯 ➡️you’ll find more. @OncoAlert @curecc #ESMOAsia22 @myESMO https://twitter.com/jdekervel/status/1598599792749600770

Jeroen Dekervel@JDekervel

Impact of molecular driver in #cholangiocarcinoma regarding #durvalumab benefit in #TOPAZ1. Exploratory but some signal for 🔽 efficacy in ERBB2 amp and IDH1mt and 🔼 efficacy in KRASmt. #ESMOAsia22 2

Reply on Twitter 1598644651665268736Retweet on Twitter 15986446516652687369Like on Twitter 159864465166526873634Twitter 1598644651665268736
VJOncologyVJ Oncology@VJOncology·
December 2, 2022

#SABCS22 starts in only a couple of days!

Stay tuned right here 👉http://VJOncology.com👈 which will be updated soon on all the latest in #BreastCancer 👩‍⚕‍🎥🎙

@VJOncology @SABCSSanAntonio @AACR #BreastCancer #BCsm #OncoAlert

Reply on Twitter 1598694368269025282Retweet on Twitter 1598694368269025282Like on Twitter 15986943682690252822Twitter 1598694368269025282
Retweet on TwitterVJ Oncology Retweeted
matteolambeMatteo Lambertini, MD PhD@matteolambe·
December 2, 2022

Great comprehensive presentation by super @RebeccaDSing at #ESMOasia22 on #immunotherapy in early triple-negative #BreastCancer: important citation for the recent review by @ElisaAgostinett & the great algorithm for #TNBC treatment by @hoperugo

@OncoAlert @myESMO #bcsm #ImmOnc

4
Reply on Twitter 1598530488737619971Retweet on Twitter 15985304887376199716Like on Twitter 159853048873761997119Twitter 1598530488737619971
Load More

Latest Videos from ESMO 2021

View all
4:11
Personalized, neoantigen-directed immunotherapy in patients with advanced MSS-CRC, GEA and NSCLC
Daniel Catenacci • 27 Aug 2021
1:19
Testing HRD in the clinic
Isabelle Ray-Coquard • 1 Sep 2021
1:43
Gastroesophageal carcinoma with HER2 gene amplification
Daniel Catenacci • 27 Aug 2021
4:10
MAHOGANY: margetuximab and retifanlimab in HER2+, 1L unresectable/metastatic GEA
Daniel Catenacci • 27 Aug 2021

Live in Paris from ESMO 2021

View all
3:58
Pembrolizumab in combination with sEphB4-HSA (B4) in previously treated mUC
Enrique Grande • 17 Sep 2021
3:09
Prostate cancer updates at ESMO 2021: STAMPEDE and PEACE-1
Silke Gillessen • 17 Sep 2021
1:30
Survivorship challenges in prostate cancer
Silke Gillessen • 17 Sep 2021
4:33
Adjuvant checkpoint blockade in high-risk urothelial and kidney cancer
Thomas Powles • 18 Sep 2021

Breast Cancer at ESMO 2021

View all
4:46
Entinostat, nivolumab and ipilimumab in advanced HER2-negative breast cancer
Evanthia T. Roussos Torres • 14 Sep 2021
3:23
Combining epigenetic modulators and immune checkpoint blockade in cancer
Evanthia T. Roussos Torres • 14 Sep 2021
3:22
Impact of metastases-directed radiation therapy on CDK4/6 inhibitors treatment for mBC
Icro Meattini • 8 Sep 2021
2:34
ELEANOR: real-world use of neratinib in HER2+, early breast cancer
Nadia Harbeck • 18 Sep 2021

Skin Cancer at ESMO 2021

View all
0:48
Targeting C/EBPβ in melanoma
Meredith McKean • 23 Sep 2021
0:43
KEYNOTE-716: adjuvant pembrolizumab for high-risk melanoma
Jason Luke • 21 Sep 2021
1:11
Highlights for skin cancer at ESMO 2021
Jason Luke • 21 Sep 2021
1:30
Adjuvant therapy for high-risk melanoma
Jason Luke • 21 Sep 2021

Genitourinary Cancer at ESMO 2021

View all
3:42
NORSE: erdafitinib + cetrelimab in mUC with FGFR alterations
Thomas Powles • 18 Sep 2021
3:09
Prostate cancer updates at ESMO 2021: STAMPEDE and PEACE-1
Silke Gillessen • 17 Sep 2021
3:58
Pembrolizumab in combination with sEphB4-HSA (B4) in previously treated mUC
Enrique Grande • 17 Sep 2021
6:12
Neoadjuvant enoblituzumab for localized prostate cancer
Eugene Shenderov • 17 Sep 2021
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals